{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"33","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. The 6-month PFS rate was estimated using the Kaplan-Meier method which can provide a point estimate for any specific time point. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Subprotocol R"}],"paramType":"NUMBER","populationDescription":"eligible and treated patients","reportingStatus":"POSTED","timeFrame":"assessed at baseline, then every 2 cycles until disease progression, up to 3 years post registration","title":"6-month Progression-free Survival (PFS) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}